On January 30, 2026, the Supreme Court of India delivered a 99-page judgment in Yash Charitable Trust & Ors. v. Union of India, ruling that stem cell therapy (SCT) for Autism Spectrum Disorder (ASD) cannot be offered as a routine clinical service.
Parental Concern
Parents of affected children go through a lot, witnessing and coping with struggles daily. However, even though some families were present and had important views and experiences to share, the court made its decision without formally hearing from the affected families. And while this judgment held that parents need to be better-informed to provide consent, many families opine that this ruling has weakened parents’ authority to make medical decisions for their children.
The primary concern for parents from the Parents Forum for Stem Cells in Autism and Cerebral Palsy is that the vital progress observed in their children will be either delayed or hindered, if treatments are stopped without warning. Medical experts, too, have voiced similar opinions.
Parents from the forum and other groups have recorded numerous improvements in their children. With therapy, 3.7-year-old Reyansh, a completely nonverbal child, began reciting the alphabet. Many children have also reported noticeable improvements in sleep patterns and eating habits.
Issues faced by affected children and their families.
While the court claims to phase over such successful cases into supervised, cost-free clinical trials, the current infrastructure for these studies is insufficient. For a trial to be “gold standard” and satisfy the Court’s demand for scientific proof, it must be double-blind and placebo-controlled. This may present distressing consequences, such as regression risk and delayed treatments for affected families.
A case in point is that of Adisesh, a 3rd grader. After years of unsuccessful treatments, stem cell therapy sparked a breakthrough in him when he began thinking logically, communicating clearly with his friends, and even playing the piano alongside his seniors. He even gained enough confidence to attend school independently. But with a single round of treatment left, his entire developmental journey seems to be in jeopardy, as he can no longer access therapy.
The forum is now requesting that existing patients be allowed to finish treatment at their own risk. The main reason is to prevent any delay in progress. So is waiting for concerned authorities to establish time-consuming infrastructure, which may cause their children to miss the treatment window.
As legal guardians with the right to choose medical care for their children, it is particularly heartbreaking for them to see their child’s progress facing roadblocks, especially from milestones they worked hard to achieve.
Another case in point is that of Vihaan, who was finally gaining independence with his sole guardian and grandmother, Dalip Kaur’s help. Vihaan showed great progress in recognising people, connecting and talking with them. However, Dalip fears what may come of Vihaan when age no longer allows her to look after Vihaan. The recent ruling, where Dalip was never given a chance to voice her concerns, threatens the boy’s progress.
What do parents and experts want?
A major concern with this judgment is that the Court has effectively overridden the relatively recent 2019 New Drugs and Clinical Trials Rules, which define stem cell derived products as a new drug, and instead relied on the 80-year-old definitions under Section 3(b)(i) of the Drugs and Cosmetics Act, 1940 on the basis of which it classifies autologous cells as a drug.
The judgement, appears to treat stem cell–derived products and autologous medical procedures as if they are the same thing. This blurs an important distinction that the updated regulatory framework itself recognises.
It is somewhat like saying that a play performed in a theatre and a film produced for cinema are the same, and therefore all stage plays must obtain film censorship approval. In reality, They are fundamentally different forms and cannot be regulated in the same manner.
Also, to balance safety and innovation, caregivers and legal experts propose that courts move toward a Rights-Based Framework, where patient autonomy is recognised, and a compassionate use protocol is established to continue treating existing patients showing developmental milestones. Setting up financial helpdesks will also help ease worries, and counselling may offer emotional support.
The government, too, is taking measures to ease the woes of parents and families of affected children.
The Ministry of Health and Family Welfare (MoHFW) has been directed to move beyond regulation and provide active, compassionate guidance. The ministry needs to undertake immediate infrastructure expansion and publish a national Autism Care plan that directs safe tapering protocols and alternative therapies.
The Logical Indian take
Though the Supreme Court’s ruling protects against medical treatments that require more research, parental involvement need not be left out. Opinions of concerned authorities, too, need adequate representation.
The court, in the ruling, stressed that patients and families must be clearly informed whether the treatment is approved or still experimental, along with its associated risks and benefits. However, when it comes to children, informed consent becomes even more important, as parents make decisions on a child’s behalf. And if parents aren’t given full and honest disclosure, the consent isn’t truly informed. This can lead to ethical issues and emotional stress.
At the same time, parents are not merely observers, they are the primary decision-makers and caregivers. Their voices, experiences, and concerns deserve meaningful consideration in any policy or judicial process affecting their children.
The right to access healthcare and explore potential therapeutic options also flows from the broader fundamental right to health under Article 21 of the Constitution of India, which has been repeatedly interpreted by courts to include the right to live with dignity and access necessary medical care. For many families navigating autism, this right translates into the ability to seek interventions that may improve a child’s quality of life, particularly when conventional options remain limited.
Parental testimonies, lived experiences, and objective evidence of observed improvements should be heard and carefully examined. Growing body of peer-reviewed scientific literature emerging from all over the world that demonstrates the beneficial role of cellular therapies in Autism should be considered. Scientific progress often evolves through observation, study, and refinement.
The government and concerned authorities now need to quickly improve systems and provide support to help affected families deal with current and future challenges, without negatively impacting the progress of children with autism.
